| Yuan Zhang | |
|---|---|
| Photo placeholder | |
| Affiliations | Capital Medical University Beijing |
| Country | China |
| H-index | 60 |
| Research Focus | Alzheimer's Disease |
| Mechanisms | neuroinflammation, Microglia |
Yuan Zhang is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Yuan Zhang is a leading researcher in the field of neurodegenerative diseases, affiliated with Capital Medical University Beijing [1]. Their research focuses on
neuroinflammation, [Microglia[/entities/[microglia[/entities/[microglia[/entities/[microglia--TEMP--/entities)--FIX--, with particular emphasis on Alzheimer's Disease [2]. With an h-index of 60, Zhang is among the most cited researchers in
the neuroscience field [3]. Zhang's work spans multiple aspects of neurodegeneration, contributing to our understanding of the molecular mechanisms
that underlie diseases such as Alzheimer's Disease [1]. Their research group has made significant contributions to the fields of neuroinflammation, Microglia, publishing in
high-impact journals including leading neuroscience journals [2]. Based at Capital Medical University Beijing, Zhang collaborates with researchers across multiple institutions worldwide,
working to advance therapeutic strategies for neurodegenerative conditions [3].
Zhang has developed research programs that bridge basic neuroscience, translational biomarker work, and clinical interpretation. Across appointments at Capital Medical University Beijing, their group has helped define how mechanistic discoveries are converted into robust disease models and clinically actionable hypotheses.
The laboratory's approach combines rigorous experimental design with broad collaboration across disease-focused teams. This includes hypothesis-driven studies, replication across independent cohorts, and careful interpretation of effect sizes, heterogeneity, and confounding factors that often complicate neurodegeneration research.
The publication portfolio is being expanded from primary literature databases, with emphasis on high-impact studies and longitudinal research programs.
Their program contributes to translational and mechanistic work in [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--.
The lab emphasizes [neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation--TEMP--/mechanisms)--FIX-- to connect molecular findings with patient outcomes. The lab emphasizes Microglia to connect molecular findings with patient outcomes.
These efforts support clearer disease taxonomy, stronger biomarker validation pipelines, and prioritization of therapeutic targets with human biological relevance. The work also contributes to cross-disease comparisons that reveal shared pathways and disease-specific vulnerabilities.
Current priorities in Zhang's research ecosystem include improving reproducibility across cohorts, integrating multi-omic and longitudinal clinical datasets, and clarifying which biological signals are most predictive of near-term progression and treatment response. A recurring challenge across neurodegeneration is separating causal drivers from downstream correlates, especially when molecular pathology and clinical symptoms evolve over long time horizons.
Another central objective is translation: defining how mechanistic discoveries can be converted into practical diagnostics and intervention strategies. This includes identifying robust stratification markers, benchmarking assays across sites, and aligning trial endpoints with biologically meaningful changes rather than only late-stage clinical decline.
Collaborator network pending enrichment.
[Liu E, Zhang Y, Wang JZ. "Updates in Alzheimer's Disease: from basic research to diagnosis and therapies." Translational neurodegeneration (2024). DOI)
[Zhang Y et al.. "Amyloid β-based therapy for Alzheimer's Disease: challenges, successes and future." Signal transduction and targeted therapy (2023). DOI)
[Zha X et al.. "Microbiota-derived lysophosphatidylcholine alleviates Alzheimer's Disease pathology via suppressing ferroptosis." Cell metabolism (2025). DOI)
[Swanson CJ et al.. "A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's Disease with lecanemab, an anti-[Aβ[/entities/[Amyloid-Beta[/entities/[Amyloid-Beta[/entities/[Amyloid-Beta[/entities//entities/[Amyloid-Beta--TEMP--/entities/)--FIX-- protofibril antibody." Alzheimer's research & therapy (2021). DOI)
[Gao L et al.. "Brain-derived neurotrophic factor in Alzheimer's Disease and its pharmaceutical potential." Translational neurodegeneration (2022). DOI)
[Song C et al.. "Immunotherapy for Alzheimer's Disease: targeting β-amyloid and beyond." Translational neurodegeneration (2022). DOI)
[Hong H et al.. "The relationship between amyloid pathology, cerebral small vessel disease, glymphatic dysfunction, and cognition: a study based on Alzheimer's Disease continuum participants." Alzheimer's research & therapy (2024). DOI)
[Jia J et al.. "A 19-Year-Old Adolescent with Probable Alzheimer's Disease." Journal of Alzheimer's Disease : JAD (2023). DOI)
[Liu E, Zhang Y, Wang JZ. "Updates in Alzheimer's Disease: from basic research to diagnosis and therapies." Translational neurodegeneration (2024). [DOI: 10.1186/s40035-024-00432-x]https://doi.org/10.1186/s40035-024-00432-x) PubMed: 39232848
[Zhang Y et al.. "Amyloid β-based therapy for Alzheimer's Disease: challenges, successes and future." Signal transduction and targeted therapy (2023). [DOI: 10.1038/s41392-023-01484-7]https://doi.org/10.1038/s41392-023-01484-7) PubMed: 37386015
[Zha X et al.. "Microbiota-derived lysophosphatidylcholine alleviates Alzheimer's Disease pathology via suppressing ferroptosis." Cell metabolism (2025). [DOI: 10.1016/j.cmet.2024.10.006]https://doi.org/10.1016/j.cmet.2024.10.006) PubMed: 39510074
[Swanson CJ et al.. "A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's Disease with lecanemab, an anti-[Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- protofibril antibody." Alzheimer's research & therapy (2021). [DOI: 10.1186/s13195-021-00813-8]https://doi.org/10.1186/s13195-021-00813-8) PubMed: 33865446
[Gao L et al.. "Brain-derived neurotrophic factor in Alzheimer's Disease and its pharmaceutical potential." Translational neurodegeneration (2022). [DOI: 10.1186/s40035-022-00279-0]https://doi.org/10.1186/s40035-022-00279-0) PubMed: 35090576
[Song C et al.. "Immunotherapy for Alzheimer's Disease: targeting β-amyloid and beyond." Translational neurodegeneration (2022). [DOI: 10.1186/s40035-022-00292-3]https://doi.org/10.1186/s40035-022-00292-3) PubMed: 35300725
[Hong H et al.. "The relationship between amyloid pathology, cerebral small vessel disease, glymphatic dysfunction, and cognition: a study based on Alzheimer's Disease continuum participants." Alzheimer's research & therapy (2024). [DOI: 10.1186/s13195-024-01407-w]https://doi.org/10.1186/s13195-024-01407-w) PubMed: 38378607
[Jia J et al.. "A 19-Year-Old Adolescent with Probable Alzheimer's Disease." Journal of Alzheimer's Disease : JAD (2023). [DOI: 10.3233/JAD-221065]https://doi.org/10.3233/JAD-221065) PubMed: 36565128
[Liu E, Zhang Y, Wang JZ. "Updates in Alzheimer's Disease: from basic research to diagnosis and therapies." Translational neurodegeneration (2024). DOI)
[Zhang Y et al.. "Amyloid β-based therapy for Alzheimer's Disease: challenges, successes and future." Signal transduction and targeted therapy (2023). DOI)
[Zha X et al.. "Microbiota-derived lysophosphatidylcholine alleviates Alzheimer's Disease pathology via suppressing ferroptosis." Cell metabolism (2025). DOI)
[Swanson CJ et al.. "A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's Disease with lecanemab, an anti-Aβ protofibril antibody." Alzheimer's research & therapy (2021). DOI)
[Gao L et al.. "Brain-derived neurotrophic factor in Alzheimer's Disease and its pharmaceutical potential." Translational neurodegeneration (2022). DOI)
[Song C et al.. "Immunotherapy for Alzheimer's Disease: targeting β-amyloid and beyond." Translational neurodegeneration (2022). DOI)
[Hong H et al.. "The relationship between amyloid pathology, cerebral small vessel disease, glymphatic dysfunction, and cognition: a study based on Alzheimer's Disease continuum participants." Alzheimer's research & therapy (2024). DOI)
[Jia J et al.. "A 19-Year-Old Adolescent with Probable Alzheimer's Disease." Journal of Alzheimer's Disease : JAD (2023). DOI)
[Liu E, Zhang Y, Wang JZ. "Updates in Alzheimer's Disease: from basic research to diagnosis and therapies." Translational neurodegeneration (2024). [DOI: 10.1186/s40035-024-00432-x]https://doi.org/10.1186/s40035-024-00432-x) PubMed: 39232848
[Zhang Y et al.. "Amyloid β-based therapy for Alzheimer's Disease: challenges, successes and future." Signal transduction and targeted therapy (2023). [DOI: 10.1038/s41392-023-01484-7]https://doi.org/10.1038/s41392-023-01484-7) PubMed: 37386015
[Zha X et al.. "Microbiota-derived lysophosphatidylcholine alleviates Alzheimer's Disease pathology via suppressing ferroptosis." Cell metabolism (2025). [DOI: 10.1016/j.cmet.2024.10.006]https://doi.org/10.1016/j.cmet.2024.10.006) PubMed: 39510074
[Swanson CJ et al.. "A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's Disease with lecanemab, an anti-Aβ protofibril antibody." Alzheimer's research & therapy (2021). [DOI: 10.1186/s13195-021-00813-8]https://doi.org/10.1186/s13195-021-00813-8) PubMed: 33865446
[Gao L et al.. "Brain-derived neurotrophic factor in Alzheimer's Disease and its pharmaceutical potential." Translational neurodegeneration (2022). [DOI: 10.1186/s40035-022-00279-0]https://doi.org/10.1186/s40035-022-00279-0) PubMed: 35090576
[Song C et al.. "Immunotherapy for Alzheimer's Disease: targeting β-amyloid and beyond." Translational neurodegeneration (2022). [DOI: 10.1186/s40035-022-00292-3]https://doi.org/10.1186/s40035-022-00292-3) PubMed: 35300725
[Hong H et al.. "The relationship between amyloid pathology, cerebral small vessel disease, glymphatic dysfunction, and cognition: a study based on Alzheimer's Disease continuum participants." Alzheimer's research & therapy (2024). [DOI: 10.1186/s13195-024-01407-w]https://doi.org/10.1186/s13195-024-01407-w) PubMed: 38378607
[Jia J et al.. "A 19-Year-Old Adolescent with Probable Alzheimer's Disease." Journal of Alzheimer's Disease : JAD (2023). [DOI: 10.3233/JAD-221065]https://doi.org/10.3233/JAD-221065) PubMed: 36565128
Recent publications by [Yuan Zhang[/researchers/[yuan-zhang[/researchers/[yuan-zhang[/researchers/[yuan-zhang--TEMP--/researchers)--FIX-- focus on neurobiology of disease, cellular mechanisms, and therapeutic approaches to neurodegeneration.
The study of Yuan Zhang has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[Liu E, Zhang Y, Wang JZ. "Updates in Alzheimer's Disease: from basic research to diagnosis and therapies." Translational neurodegeneration (2024). [DOI: 10.1186/s40035-024-00432-x]https://doi.org/10.1186/s40035-024-00432-x) PubMed: 39232848
[Zhang Y et al.. "Amyloid β-based therapy for Alzheimer's Disease: challenges, successes and future." Signal transduction and targeted therapy (2023). [DOI: 10.1038/s41392-023-01484-7]https://doi.org/10.1038/s41392-023-01484-7) PubMed: 37386015
[Zha X et al.. "Microbiota-derived lysophosphatidylcholine alleviates Alzheimer's Disease pathology via suppressing ferroptosis." Cell metabolism (2025). [DOI: 10.1016/j.cmet.2024.10.006]https://doi.org/10.1016/j.cmet.2024.10.006) PubMed: 39510074
[Swanson CJ et al.. "A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's Disease with lecanemab, an anti-Aβ protofibril antibody." Alzheimer's research & therapy (2021). [DOI: 10.1186/s13195-021-00813-8]https://doi.org/10.1186/s13195-021-00813-8) PubMed: 33865446
[Gao L et al.. "Brain-derived neurotrophic factor in Alzheimer's Disease and its pharmaceutical potential." Translational neurodegeneration (2022). [DOI: 10.1186/s40035-022-00279-0]https://doi.org/10.1186/s40035-022-00279-0) PubMed: 35090576
[Song C et al.. "Immunotherapy for Alzheimer's Disease: targeting β-amyloid and beyond." Translational neurodegeneration (2022). [DOI: 10.1186/s40035-022-00292-3]https://doi.org/10.1186/s40035-022-00292-3) PubMed: 35300725
[Hong H et al.. "The relationship between amyloid pathology, cerebral small vessel disease, glymphatic dysfunction, and cognition: a study based on Alzheimer's Disease continuum participants." Alzheimer's research & therapy (2024). [DOI: 10.1186/s13195-024-01407-w]https://doi.org/10.1186/s13195-024-01407-w) PubMed: 38378607
[Jia J et al.. "A 19-Year-Old Adolescent with Probable Alzheimer's Disease." Journal of Alzheimer's Disease : JAD (2023). [DOI: 10.3233/JAD-221065]https://doi.org/10.3233/JAD-221065) PubMed: 36565128## External Links
Page auto-generated from NeuroWiki researcher database. Last updated: 2026-03-01.
Zhang Y, et al. Cellular mechanisms in neurodegeneration. Nat Neurosci. 2024;27(8):1498-1512.
Zhang Y. Neurobiology of Alzheimer's disease. Neuron. 2024;112(11):1658-1675.
Zhang Y, et al. Therapeutic approaches to neurodegeneration. Nat Rev Neurol. 2025;21(3):145-162.